ICOS

ICOS

ICOS 詳細

Molecule Name
Inducible T-cell costimulator
分子の別称
ICOS,CD278,AILIM,Inducible T-cell costimulator
Drug Development Progress
治験薬の数7
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
バックグランド
Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
VopratelimabJTX-2011Phase 2 ClinicalJounce Therapeutics Inc
Carcinoma, Non-Small-Cell Lung; Neoplasms
詳細
FeladilimabGSK-609; GSK-3359609Phase 2 ClinicalGlaxosmithkline Plc
Head and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
AcazicolceptALPN-101Phase 2 ClinicalAlpine Immune Sciences Inc
Autoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders
詳細
MEDI-570Phase 1 ClinicalJapan Tobacco (Hong Kong) Ltd
Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
詳細
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor Inc
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
Anti-ICOS (Bristol Myers Squibb)BMS-986226Phase 1 ClinicalBristol-Myers Squibb Company
Neoplasms
詳細
anti-ICOS mAb (Bristol-Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb Company
Neoplasms; Solid tumours
詳細